Albania
Bośnia i Hercegowina
Bułgaria
Chorwacja
Cypr
Czarnogóra
Czechy
Dania
Estonia
Hiszpania
Kosowo
Litwa
Łotwa
Luksemburg
Macedonia
Niemcy
Polska
Portugalia
Rumunia
Serbia
Słowacja
Słowenia
Szwajcaria
Szwecja
Turcja
Węgry
Wielka Brytania
Włochy
UAE
Hong Kong
Kuwejt
Liban
RPA
Terapie
komórkami macierzystymi
Terapie komórkami macierzystymi
Celem bankowania komórek macierzystych jest ich późniejsze wykorzystanie w terapii. Krew pępowinowa została zastosowana po raz pierwszy w 1988 roku, a od tego czasu – zgodnie z dostępnymi danymi – komórki macierzyste zostały użyte na świecie ponad 85 000 razy (łącznie ze statystykami z Chin).
Grupa FamiCord przechowuje ponad 1 000 000 porcji komórek różnych typów i dostarczyła komórki macierzyste do zastosowań klinicznych dla ponad 7000 pacjentów. Dostarczamy komórki do standardowych przeszczepień (z krwi pępowinowej, szpiku kostnego i mobilizowanej krwi obwodowej) oraz do terapii komórkowych. Ponadto wytwarzamy produkty komórkowe w standardzie GMP (ang. Good Manufacturing Practice) do badań klinicznych.
Komórki macierzyste pochodzące z naszych laboratoriów były wykorzystywane w leczeniu pacjentów z chorobami i wskazaniami z różnych obszarów terapeutycznych – m.in. hematologii, neurologii, okulistyki, ortopedii i dermatologii.
Sprawdź pełną listę pacjentów, którzy otrzymali terapię komórkami macierzystymi pochodzącymi z laboratoriów Grupy FamiCord.
Data aktualizacji: 06.2026
Lista pacjentów, którzy otrzymali komórki macierzyste z laboratoriów Grupy FamiCord
| Lp. | Źródło | Typ źródła | Wskazanie | Obszar medycyny | Rok podania | Terapia | Kraj | Wiek odbiorcy |
|---|---|---|---|---|---|---|---|---|
| 2001 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Germany | 68 |
| 2002 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Germany | 62 |
| 2003 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Germany | 48 |
| 2004 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | USA | 63 |
| 2005 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2024 | Standard Therapy | Spain | 58 |
| 2006 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2024 | Standard Therapy | Poland | 41 |
| 2007 | Apheresis | Allogeneic | Myelofibrosis Myeloid Metaplasia | Hematology | 2024 | Standard Therapy | USA | 73 |
| 2008 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 15 |
| 2009 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Germany | 65 |
| 2010 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 38 |
| 2011 | Apheresis | Allogeneic | Plasmacytoma | Hematology | 2024 | Standard Therapy | Poland | 46 |
| 2012 | Apheresis | Autologous | Multiple myeloma | Hematology | 2024 | Standard Therapy | Portugal | 60 |
| 2013 | Apheresis | Autologous | Multiple myeloma | Hematology | 2024 | Standard Therapy | Portugal | 60 |
| 2014 | Skeletal Muscle | Allogeneic – Related | Duchenne Muscular Dystrophy (DMD) | Genetic disorder | 2023 | Experimental Therapy | Poland | 8 |
| 2015 | Skeletal Muscle | Allogeneic – Related | Duchenne Muscular Dystrophy (DMD) | Genetic disorder | 2023 | Experimental Therapy | Poland | 16 |
| 2016 | Cord Tissue | Allogeneic – Related | Ags (Autism + Epilepsy) | Neurology | 2023 | Experimental Therapy | Poland/Romania | 15 |
| 2017 | Cord Tissue | Allogeneic – Related | Autism | Neurology | 2023 | Experimental Therapy | Romania | 8 |
| 2018 | Cord Tissue | Autologous | Autism | Neurology | 2023 | Experimental Therapy | Hungary | 10 |
| 2019 | Cord Tissue | Allogeneic – Related | Autism | Neurology | 2023 | Experimental Therapy | Romania | 4 |
| 2020 | Cord Tissue | Allogeneic – Related | Autism | Neurology | 2023 | Experimental Therapy | Romania | 10 |
| 2021 | Cord Tissue | Allogeneic – Related | Autism | Neurology | 2023 | Experimental Therapy | Romania | 3 |
| 2022 | Cord Tissue | Autologous | Cerebral Palsy | Neurology | 2023 | Experimental Therapy | Romania | 2 |
| 2023 | Cord Tissue | Allogeneic – Related | Cerebral Palsy | Neurology | 2023 | Experimental Therapy | Romania | 3 |
| 2024 | Cord Tissue | Allogeneic – Unrelated | Disorders Of Optic Nerve | Ophthalmology | 2023 | Experimental Therapy | Poland | 39 |
| 2025 | Cord Tissue | Allogeneic – Unrelated | Gonarthrosis | Orthopedy | 2023 | Experimental Therapy | Poland | 65 |
| 2026 | Cord Tissue | Allogeneic – Unrelated | Gonarthrosis | Orthopedy | 2023 | Experimental Therapy | Poland | 50 |
| 2027 | Cord Tissue | Allogeneic – Unrelated | Graft Versus Host Disease | Hematology | 2023 | Experimental Therapy | Poland | 8 |
| 2028 | Cord Tissue | Allogeneic – Unrelated | Graft Versus Host Disease | Hematology | 2023 | Experimental Therapy | Poland | 16 |
| 2029 | Cord Tissue | Allogeneic – Unrelated | Internal Damage To The Knee Joint | Orthopedy | 2023 | Experimental Therapy | Poland | 20 |
| 2030 | Cord Tissue | Allogeneic – Unrelated | Internal Damage To The Knee Joint | Orthopedy | 2023 | Experimental Therapy | Poland | 49 |
| 2031 | Cord Tissue | Allogeneic – Unrelated | Internal Damage To The Knee Joint | Orthopedy | 2023 | Experimental Therapy | Poland | 62 |
| 2032 | Cord Tissue | Allogeneic – Unrelated | Internal Damage To The Knee Joint | Orthopedy | 2023 | Experimental Therapy | Poland | 24 |
| 2033 | Cord Tissue | Allogeneic – Unrelated | Mucopolysaccharidosis Type Ii | Hematology | 2023 | Experimental Therapy | Poland | 4 |
| 2034 | Cord Tissue | Allogeneic – Unrelated | Non-Inflammatory Diseases Of The Ovary, Fallopian Tube, And Broad Ligament Of The Uterus | Gynecology | 2023 | Experimental Therapy | Poland | 47 |
| 2035 | Cord Tissue | Autologous | Optic Nerve Atrophy, Tetraparesis, Hydrocephalus | Neurology | 2023 | Experimental Therapy | Romania | 5 |
| 2036 | Cord Tissue | Allogeneic – Unrelated | Ovarian Dysfunction | Gynecology | 2023 | Experimental Therapy | Poland | 44 |
| 2037 | Cord Tissue | Allogeneic – Unrelated | Ovarian Dysfunction | Gynecology | 2023 | Experimental Therapy | Poland | 32 |
| 2038 | Cord Tissue | Allogeneic – Unrelated | Polycystic Ovary Syndrome | Gynecology | 2023 | Experimental Therapy | Poland | 39 |
| 2039 | Cord Tissue | Allogeneic – Related | Right Parietal Closed Schizencephaly | Neurology | 2023 | Experimental Therapy | Romania | 38 |
| 2040 | Cord Tissue | Allogeneic – Related | Rp+ Usher Syndrome | Neurology | 2023 | Experimental Therapy | Romania | 10 |
| 2041 | Cord Tissue | Allogeneic – Related | Sudden Sensorineural Hearing Loss (Ssnhl) | Neurology | 2023 | Experimental Therapy | Romania | 1 |
| 2042 | Cord Blood | Autologous | Autism | Neurology | 2023 | Experimental Therapy | Hungary | 10 |
| 2043 | Cord Blood | Allogeneic | Autism | Neurology | 2023 | Experimental Therapy | Poland | 3 |
| 2044 | Cord Blood | Autologous | Autism | Neurology | 2023 | Experimental Therapy | Romania | 3 |
| 2045 | Cord Blood | Autologous | Autism | Neurology | 2023 | Experimental Therapy | Romania | 3 |
| 2046 | Cord Blood | Autologous | Autism | Neurology | 2023 | Experimental Therapy | Romania | 10 |
| 2047 | Cord Blood | Autologous | Autism | Neurology | 2023 | Experimental Therapy | Portugal | 7 |
| 2048 | Cord Blood | Autologous | Autism | Neurology | 2023 | Experimental Therapy | Portugal | 5 |
| 2049 | Cord Blood | Autologous | Autism | Neurology | 2023 | Experimental Therapy | Hungary | 14 |
| 2050 | Cord Blood | Autologous | Autism | Neurology | 2023 | Experimental Therapy | Romania | 10 |
| 2051 | Cord Blood | Autologous | Autism | Neurology | 2023 | Experimental Therapy | Hungary | 3 |
| 2052 | Cord Blood | Allogeneic – Related | Autism | Neurology | 2023 | Experimental Therapy | Romania | 3 |
| 2053 | Cord Blood | Autologous | Autism | Neurology | 2023 | Experimental Therapy | Hungary | 5 |
| 2054 | Cord Blood | Allogeneic – Related | Beta Thalassemia | Hematology | 2023 | Standard Therapy | UK | 8 |
| 2055 | Cord Blood | Allogeneic – Related | Cerebral Palsy | Neurology | 2023 | Experimental Therapy | Hungary | 5 |
| 2056 | Cord Blood | Allogeneic – Related | Cerebral Palsy | Neurology | 2023 | Standard Therapy | UK | 2 |
| 2057 | Cord Blood | Allogeneic – Related | Cerebral Palsy | Neurology | 2023 | Standard Therapy | UK | 2 |
| 2058 | Cord Blood | Autologous | Cerebral Palsy | Neurology | 2023 | Experimental Therapy | Poland | 2 |
| 2059 | Cord Blood | Allogeneic – Related | Cerebral Palsy | Neurology | 2023 | Experimental Therapy | Romania | 10 |
| 2060 | Cord Blood | Allogeneic – Related | Cerebral Palsy, Psychomotor Retard, Tetraparesis, Microcephaly | Neurology | 2023 | Experimental Therapy | Romania | 9 |
| 2061 | Cord Blood | Autologous | Global Developmental Delay Si Truncal Ataxia | Neurology | 2023 | Experimental Therapy | Romania | 5 |
| 2062 | Cord Blood | Allogeneic | Neuroblastoma | Hematology | 2023 | Standard Therapy | Turkey | 2 |
| 2063 | Cord Blood | Allogeneic – Related | Neuroblastoma | Hematology | 2023 | Standard Therapy | Turkey | 2 |
| 2064 | Cord Blood | Autologous | Optic Nerve Atrophy, Tetraparesis, Hydrocephalus | Neurology | 2023 | Experimental Therapy | Romania | 5 |
| 2065 | Cord Blood | Autologous | Pervasive Developmental Disorder | Neurology | 2023 | Experimental Therapy | Poland | 3 |
| 2066 | Cord Blood | Autologous | Pervasive Developmental Disorder | Neurology | 2023 | Experimental Therapy | Poland | 8 |
| 2067 | Cord Blood | Allogeneic – Related | Spasmodic Torticollis | Neurology | 2023 | Experimental Therapy | Romania | 41 |
| 2068 | Cord Blood | Allogeneic | Thalassemia Major | Hematology | 2023 | Standard Therapy | Turkey | 17 |
| 2069 | Cord Blood | Allogeneic – Related | Thalassemia Major | Hematology | 2023 | Standard Therapy | Turkey | 17 |
| 2070 | Cord Blood | Allogeneic | Wiskott-Aldrich Syndrome | Hematology | 2023 | Standard Therapy | Poland | 5 |
| 2071 | Cord Blood | Autologous | Autism | Neurology | 2023 | Experimental Therapy | Slovakia | 2 |
| 2072 | Bone Marrow Family | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 42 |
| 2073 | Bone Marrow Family | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 41 |
| 2074 | Bone Marrow Family | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Germany | 35 |
| 2075 | Bone Marrow Family | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 59 |
| 2076 | Bone Marrow Family | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 50 |
| 2077 | Bone Marrow Family | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 51 |
| 2078 | Bone Marrow Family | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 59 |
| 2079 | Bone Marrow Family | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 42 |
| 2080 | Bone Marrow Family | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 21 |
| 2081 | Bone Marrow Family | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 67 |
| 2082 | Bone Marrow Family | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 63 |
| 2083 | Bone Marrow Family | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 39 |
| 2084 | Bone Marrow Family | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 53 |
| 2085 | Bone Marrow Family | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 42 |
| 2086 | Bone Marrow Family | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 62 |
| 2087 | Bone Marrow Family | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 49 |
| 2088 | Bone Marrow Family | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 61 |
| 2089 | Bone Marrow Family | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 43 |
| 2090 | Bone Marrow Family | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 57 |
| 2091 | Bone Marrow Family | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 56 |
| 2092 | Bone Marrow Family | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 55 |
| 2093 | Bone Marrow Family | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 63 |
| 2094 | Bone Marrow Family | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 55 |
| 2095 | Bone Marrow Family | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 61 |
| 2096 | Bone Marrow Family | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 47 |
| 2097 | Bone Marrow Family | Allogeneic | B-Cell Precursor Acute Lymphocytic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 30 |
| 2098 | Bone Marrow Family | Allogeneic | Chronic Lymphocytic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 69 |
| 2099 | Bone Marrow Family | Allogeneic | Chronic Myelomonocytic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 60 |
| 2100 | Bone Marrow Family | Allogeneic | Chronic Myelomonocytic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 70 |